ClinicalTrials.gg
CompletedNCT00944034Updated Aug 14, 2017Results posted

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

A Phase 2/3 interventional study of rMenB+OMV NZ with routine vaccinations and rMenB+OMV NZ with routine vaccinations in Meningococcal Disease and Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 72 sites in 6 countries. Open to participants aged 12 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-14.

Primary conditionMeningitis, MeningococcalRegistry: Meningococcal InfectionsReclassifiedWhy we changed it
Registry
Meningococcal Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningococcal Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,588
Allocation
Randomized
Ages
12 Months to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.

Enrollment
Largest of 11
1,588 · median 250
Started
2009
with 1 other
Phase 2/3
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
4 of 11
Novartis Vaccines

Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one has the largest enrollment, is one of 2 that started in 2009, is the only one in phase 2/3, and was the 3rd registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 12 Months to 24 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, or all of them as a file.
02

Study summary

This extension study V72P12E1 will investigate the safety, tolerability and immunogenicity of a fourth (booster) dose of rMenB+OMV NZ at 12, 18 and 24 months of age in subjects previously primed with rMenB+OMV NZ according to two different three-dose immunization schedules in infancy (2, 4 and 6 or 2, 3 and 4 months of age in the parent study V72P12). The study will also explore the bactericidal antibody persistence at 12, 18 and 24 months of age, following the two different immunization schedules, in order to identify the optimal timing for boosting. Two catch-up rMenB+OMV NZ doses will be given to unprimed, naïve toddlers at 12 (subjects enrolled in the control group of V72P12), 18 and 24 months of age (two new cohort of subjects enrolled). These subjects will generate data for assessing the safety and immunogenicity of a two-dose catch-up regimen at these ages, but will also serve as controls for a descriptive comparison of antibody persistence and booster responses for the other groups.

03

Conditions studied

  • Meningococcal Disease
  • Meningococcal Meningitis

Browse trials for

Keywords

  • Meningococcal meningitis
  • prevention
  • vaccination
  • toddler
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 1,588 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.

First submitted before Novartis Vaccines left Novartis.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningococcal Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Months to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Follow-on participants of V72P12:

Healthy toddlers who completed Study V72P12, aged:

  • 12 months or older - Groups 1a, 2a, 3a, 4
  • 18 months (0/ +29 days window) - Groups 1b, 2b, 3b
  • 24 months (0/ +29 days window) - Groups 1c, 2c, 3c

Naive subjects newly enrolled:

  • Group 5: healthy 18-month-old toddlers (0/ +29 days window)
  • Group 6: healthy 24-month-old toddlers (0/ +29 days window)

Exclusion criteria

Exclusion Criteria:

  • History of any meningococcal B vaccine administration (only for groups 5 and 6);
  • Previous ascertained or suspected disease caused by N. meningitidis;
  • History of severe allergic reaction after previous vaccinations or to any vaccine component;
  • Significant acute or chronic infection within the previous 7 days or axillary temperature major or equal to 38 degrees within the previous day
  • Antibiotics within 6 days prior to enrollment;
  • Any serious chronic or progressive disease;
  • Known or suspected impairment or alteration of the immune system;
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,588 participants (actual)

Study arms

  • Experimental
    B+R246_12

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B+R246_18

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B+R246_24

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B246_12

    Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B246_18

    Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B246_24

    Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.

    Biological: rMenB+OMV NZ

  • Experimental
    B+R234_12

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B+R234_18

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B+R234_24

    Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

    Biological: rMenB+OMV NZ with routine vaccinations

  • Experimental
    B12 14

    Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.

    Biological: two doses of rMenB+OMV NZ

  • Experimental
    B18 20

    Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.

    Biological: two doses of rMenB+OMV NZ

  • Experimental
    B24 26

    Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.

    Biological: two doses of rMenB+OMV NZ

Interventions

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age

  • Biologicaltwo doses of rMenB+OMV NZ

    two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age

  • Biologicaltwo doses of rMenB+OMV NZ

    two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age

  • BiologicalrMenB+OMV NZ

    Drug page: 4CMenB vaccine

    rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age

  • Biologicaltwo doses of rMenB+OMV NZ

    two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age

  • BiologicalrMenB+OMV NZ with routine vaccinations

    rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age

07

What researchers measure

Primary outcomes

  1. Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.

    Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.

    Time frame: 1 month after booster

Secondary outcomes

  1. Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.

    Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.

    Time frame: 1 month after booster

  2. Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.

    Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.

    Time frame: 1 month after booster

  3. Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.

    The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

    Time frame: 1 month after booster

  4. GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age

    Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

    Time frame: 1 month after booster

  5. GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age

    Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

    Time frame: 1 month after booster

  6. Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months

    Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

    Time frame: 1 month after second vaccination

  7. Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.

    Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.

    Time frame: 1 month after booster vaccination

  8. Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.

    Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA

    Time frame: 1 month after booster vaccination

  9. Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.

    The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

    Time frame: From day 1 to day 7 after vaccination

  10. Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.

    The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

    Time frame: day 1 to day 7 after vaccination

08

Results

Posted Nov 10, 2015
Limitations and caveats
None reported

Participant flow

Subjects were enrolled from 6 centres in Belgium, 4 in Czech, 24 in Germany, 5 in Italy, 16 in Spain and 4 in UK who had previously participated in and completed the study V72P12.

Participant flow — Overall Study
MilestoneB+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26
Started18815715217416414310678732465156
Completed18315014317015012310273632365052
Not completed5794142045101014
Withdrew: Inappropriate enrollment010121001100
Withdrew: Withdrawal by subject326258223404
Withdrew: Lost to follow-up042057015110
Withdrew: Death001000000000
Withdrew: Protocol violation200123011400
Withdrew: Unable to classify000001110000
Withdrew: Administrative reason000000100000

Outcome measures

PrimaryPercentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.

Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.

Time frame:
1 month after booster
Reported as:
Number · percentage of subjects
Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.
percentage of subjectsB+R246_12B+R246_18B+R246_24
hSBA≥ 1: 5 (H44/76 strain)(N = 158,116,101)97 (93 to 99)100 (96 to 100)100 (95 to 100)
hSBA≥ 1: 5 (5/99 strain)(N= 156,118,100)100 (97 to 100)100 (96 to 100)100 (95 to 100)
hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,118,103)95 (89 to 98)77 (67 to 86)84 (74 to 92)
hSBA≥ 1: 5 (M10713 strain)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.

Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.

Time frame:
1 month after booster
Reported as:
Number · percentage of subjects
Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.
percentage of subjectsB246_12B246_18B246_24
hSBA≥ 1: 5 (H44/76 strain)(N= 138,111,93)100 (97 to 100)99 (94 to 100)100 (95 to 100)
hSBA≥ 1: 5 (5/99 strain)(N= 142,110,92)100 (97 to 100)100 (96 to 100)100 (95 to 100)
hSBA≥ 1: 5 (NZ 98/254 strain)(N= 142,111,95)96 (90 to 99)86 (76 to 93)89 (80 to 96)
hSBA≥ 1: 5 (M10713 strain)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPercentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.

Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.

Time frame:
1 month after booster
Reported as:
Number · percentage of subjects
Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.
percentage of subjectsB+R234_12B+R234_18B+R234_24
hSBA≥ 1: 5 (H44/76 strain)(N= 83,56,48 )100 (94 to 100)98 (88 to 100)100 (91 to 100)
hSBA≥ 1: 5 (5/99 strain)(N= 84,56,46)100 (94 to 100)100 (92 to 100)100 (90 to 100)
hSBA≥ 1: 5 (NZ 98/254 strain)(N= 83,56,48)97 (89 to 100)80 (65 to 91)96 (83 to 100)
hSBA≥ 1: 5 (M10713 strain)(N= 67,50,41)76 (62 to 87)74 (57 to 87)95 (81 to 100)
SecondaryGeometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.

The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

Time frame:
1 month after booster
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.
TitersB+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24
hSBA≥ 1: 5 (H44/76 strain)125 (106 to 148)123 (101 to 149)108 (88 to 133)178 (149 to 213)164 (135 to 200)152 (122 to 188)135 (108 to 170)92 (70 to 121)128 (95 to 172)
hSBA≥ 1: 5 (5/99 strain)1276 (1092 to 1491)2183 (1824 to 2611)1820 (1497 to 2212)1713 (1454 to 2020)2058 (1710 to 2476)2739 (2233 to 3361)1558 (1262 to 1923)1486 (1148 to 1924)2081 (1564 to 2771)
hSBA≥ 1: 5 (NZ 98/254 strain)36 (29 to 44)15 (12 to 19)17 (14 to 22)34 (27 to 42)17 (14 to 22)19 (15 to 25)47 (36 to 62)17 (12 to 24)33 (23 to 47)
hSBA≥ 1: 5 (M10713 strain)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)12 (8.52 to 17)15 (10 to 23)26 (17 to 41)
SecondaryGMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age

Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

Time frame:
1 month after booster
Reported as:
Geometric mean · Titers
GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age
TitersB+R246_12B246_12B+R234_12B12 14
hSBA≥ 1: 5 (H44/76 strain)(N= 158,138,83,217)125 (102 to 154)179 (144 to 223)137 (104 to 181)18 (15 to 21)
hSBA≥ 1: 5 (5/99 strain)(N= 156,142,84,216)1301 (1076 to 1573)1763 (1441 to 2157)1607 (1243 to 2077)49 (42 to 58)
hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,142,86,220)37 (29 to 46)35 (27 to 44)48 (36 to 65)3.71 (3.06 to 4.5)
SecondaryGMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age

Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

Time frame:
1 month after booster
Reported as:
Geometric mean · Titers
GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age
TitersB+R246_18B+R246_24B246_18B246_24B+R234_18B+R234_24B18 20B24 26
hSBA≥ 1: 5 (H44/76 strain)126 (104 to 154)110 (89 to 136)162 (132 to 198)155 (124 to 193)93 (70 to 123)132 (97 to 180)18 (13 to 25)14 (10 to 19)
hSBA≥ 1: 5 (5/99 strain)2195 (1790 to 2691)1811 (1449 to 2262)2034 (1648 to 2511)2735 (2166 to 3455)1483 (1107 to 1986)2087 (1508 to 2889)41 (30 to 56)30 (22 to 41)
hSBA≥ 1: 5 (NZ 98/254 strain)16 (12 to 20)18 (14 to 23)17 (14 to 22)20 (15 to 26)17 (12 to 25)34 (23 to 49)2.76 (1.87 to 4.08)2.1 (1.44 to 3.07)
SecondaryTwo-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months

Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

Time frame:
1 month after second vaccination
Reported as:
Geometric mean · Titers
Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months
TitersB12 14B18 20B24 26
hSBA≥ 1: 5 (H44/76 strain)(N= 156,42,45)188 (164 to 216)171 (130 to 224)177 (136 to 231)
hSBA≥ 1: 5 (5/99 strain)(N= 177, 40,46)635 (548 to 735)491 (359 to 672)559 (417 to 749)
hSBA≥ 1: 5 (NZ 98/254 strain)(N = 179,44,45)40 (35 to 47)23 (17 to 30)24 (18 to 32)
hSBA≥ 1: 5 (M10713 strain)(N= 0,34,37)NA (NA to NA)14 (8.02 to 23)18 (11 to 29)
SecondaryGeometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.

Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.

Time frame:
1 month after booster vaccination
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.
IU/mLB+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.5334 (4670 to 6093)6395 (5474 to 7470)6864 (5826 to 8087)6605 (5733 to 7609)6418 (5477 to 7520)8120 (6833 to 9649)6125 (5110 to 7342)5952 (4771 to 7426)6774 (5305 to 8649)
SecondaryGeometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.

Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA

Time frame:
1 month after booster vaccination
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.
IU/mLB12 14B18 20B24 26
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.122 (101 to 147)121 (84 to 176)100 (69 to 144)
SecondaryNumber of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.

The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

Time frame:
From day 1 to day 7 after vaccination
Reported as:
Number · participants
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.
participantsB246_12B246_18B246_24
Any156135116
Any Local137119113
Injection site Tenderness104104105
Injection site Erythema1179494
Injection site Induration936273
Injection site Swelling575250
Any Systemic134118101
ChangeEat.Habits665951
Sleepiness635652
Vomiting898
Diarrhea372327
Irritbility1049183
Unusual Crying525140
Rash737
Fever ( >= 38C )525528
Any Ohter595940
Body Temp. <38 C1189898
Medical Attend. Fever552
Antipyretic prophylactic322825
Antipyretic therapeutic373921
SecondaryNumber of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.

The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

Time frame:
day 1 to day 7 after vaccination
Reported as:
Number · participants
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.
participantsB12 14B18 20B24 26
Injection site Tenderness (vaccination 1)1513547
Injection site Tenderness (vaccination 2)1433242
Injection site Erythema (vaccination 1)1513239
Injection site Erythema (vaccination 2)1483331
Injection site Induration (vaccination 1)1122027
Injection site Induration (vaccination 2)1012422
Injection site Swelling (vaccination 1)811519
Injection site Swelling (vaccination 2)721819
Change in Eating habits (vaccination 1)951325
Change in Eating habits (vaccination 2)831921
Sleepiness (vaccination 1)1062118
Sleepiness (vaccination 2)781618
Vomiting (vaccination 1)1956
Vomiting (vaccination 2)1814
Diarrhea (vaccination 1)431320
Diarrhea (vaccination 2)3557
Irritability (vaccination 1)1562328
Irritability (vaccination 2)1262723
Unusual Crying (vaccination 1)811315
Unusual Crying (vaccination 2)671415
Rash (vaccination 1)1352
Rash (vaccination 2)1040
Fever ( >= 38C ) (vaccination 1)831415
Fever ( >= 38C ) (vaccination 2)741513
Body Temp.<38 C (vaccination 1)1563739
Body Temp.<38 C (vaccination 2)1633639
Medical Attend. Fever (vaccination 1)921
Medical Attend. Fever (vaccination 2)510
Antipyretic prophylactic (vaccination 1)4988
Antipyretic prophylactic (vaccination 2)45911
Antipyretic therapeutic (vaccination 1)66911
Antipyretic therapeutic (vaccination 2)54117

Adverse events

Collected over From day 1 to day 7 after vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B+R246_12—5/185 (2.7%)180/185 (97.3%)
B+R246_18—3/152 (2%)147/152 (96.7%)
B+R246_24—6/144 (4.2%)140/144 (97.2%)
B246_12—6/170 (3.5%)163/170 (95.9%)
B246_18—7/153 (4.6%)139/153 (90.8%)
B246_24—1/126 (0.8%)116/126 (92.1%)
B+R234_12—5/104 (4.8%)102/104 (98.1%)
B+R234_18—5/74 (6.8%)73/74 (98.6%)
B+R234_24—3/66 (4.5%)62/66 (93.9%)
B12 14—16/239 (6.7%)230/239 (96.2%)
B18 20—0/51 (0%)50/51 (98%)
B24 26—1/55 (1.8%)54/55 (98.2%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventB+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26
GastroenteritisInfections and infestations0/1851/1520/1440/1702/1530/1260/1042/740/662/2390/510/55
ConcussionInjury, poisoning and procedural complications0/1850/1520/1441/1701/1530/1260/1040/740/661/2390/511/55
Head injuryInjury, poisoning and procedural complications0/1850/1520/1440/1700/1530/1260/1040/741/661/2390/510/55
Febrile convulsionNervous system disorders0/1850/1522/1440/1700/1530/1261/1040/741/663/2390/510/55
BronchiolitisInfections and infestations0/1850/1520/1440/1700/1531/1260/1040/741/660/2390/510/55
TonsillitisInfections and infestations1/1850/1520/1440/1700/1530/1260/1040/741/660/2390/510/55
StomatitisGastrointestinal disorders0/1850/1520/1440/1700/1530/1260/1041/740/660/2390/510/55
UrticariaSkin and subcutaneous tissue disorders0/1850/1520/1440/1700/1530/1260/1041/740/660/2390/510/55
Accidental exposure to productInjury, poisoning and procedural complications0/1850/1520/1440/1700/1530/1260/1041/740/660/2390/510/55
PneumoniaInfections and infestations2/1850/1521/1440/1700/1530/1261/1040/740/660/2390/510/55
Most frequent other events
Showing 10 of 39
Most frequent other events
EventB+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26
Injection site painGeneral disorders107/185114/152118/144104/170104/153105/12670/10456/7451/66187/23941/5151/55
Injection site erythemaGeneral disorders127/185100/152109/144117/17094/15394/12676/10452/7449/66179/23938/5141/55
IrritabilityPsychiatric disorders110/185100/15292/144104/17091/15383/12672/10453/7444/66177/23932/5135/55
Injection site indurationGeneral disorders101/18574/15276/14493/17062/15373/12652/10441/7435/66148/23927/5133/55
Eating disorderPsychiatric disorders64/18570/15268/14466/17059/15351/12641/10429/7428/66126/23921/5134/55
PyrexiaGeneral disorders78/18557/15250/14460/17059/15332/12653/10428/7427/66133/23924/5122/55
SomnolenceNervous system disorders72/18561/15272/14463/17056/15352/12650/10433/7427/66129/23925/5128/55
Injection site swellingGeneral disorders73/18553/15263/14457/17052/15350/12632/10436/7425/66107/23921/5124/55
CryingGeneral disorders56/18543/15246/14452/17051/15340/12641/10418/7422/66105/23917/5125/55
DiarrhoeaGastrointestinal disorders39/18526/15232/14440/17027/15327/12621/10418/7413/6672/23916/5121/55

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)B+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26Total
<=18 years188157152174164143106787324651561588
Between 18 and 65 years0000000000000
>=65 years0000000000000
Age, Continuous
Age, Continuous(months)B+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26Total
Mean12.6 ± 1.218.1 ± 0.624 ± 0.412.7 ± 0.918.1 ± 0.524 ± 0.312.8 ± 1.418 ± 0.424 ± 0.512.6 ± 1.318 ± 0.224 ± 0.217.1 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)B+R246_12B+R246_18B+R246_24B246_12B246_18B246_24B+R234_12B+R234_18B+R234_24B12 14B18 20B24 26Total
Female7873778180756241341152323762
Male11084759384684437391312833826
09

Study locations

72 sites
  • Avenue Albert 1er 185, 5000 Namur, Belgium
  • Avenue Hippocrate 10, 1200 Brussels, Belgium
  • Laarbeeklaan 101, 1090 Brussels, Belgium
  • Lindendreef 1, 2020 Antwerpen, Belgium
  • Sint Vincentiusstraat 20, 2018 Antwerpen, Belgium
  • Stadsomvaart 11, 3500 Hasselt, Belgium
  • Wilrijkstraat 10, 2650 Edegem, Belgium
  • Cerveny Kostelec, 549 41, Czechia
  • Kyjevska 44, 532 03 Pardubice, Czechia
  • Ruskych legii 352, 377 01 Jindrichuv Hradec, Czechia
  • Trebesska 1575, 500 01 Hradec Kralove, Czechia
  • Ahrensböker Str. 11, 23617 Stockelsdorf, Germany
  • Am Alten Hafen 117, 27568 Bremerhaven, Germany
  • Ammertalweg 7, 99086 Erfurt, Germany
  • Anne Frank Str.27, 75015 Bretten, Germany
  • Bucher Chaussee 1-3, 13125 Berlin, Germany
  • Christian-Bauer-Str.5, 73642 Welzheim, Germany
  • Deckertstr. 53, 33645 Bielefeld, Germany
  • Dingbängerweg 69, 48163 Münster, Germany
  • Elisenstr. 28, 63739 Aschaffenburg, Germany
  • Gartenstr. 3,76889 Schweigen, Germany
  • Großbottwarer Str. 47, 71720 Oberstenfeld, Germany
  • Hanseatenplatz 1, 25524 Itzehoe, Germany
  • Hauptstr. 165, 42579 Heiligenhaus, Germany
  • Hauptstr. 240, 77694 Kehl, Germany
  • Hauptstr. 46, 37083 Göttingen, Germany
  • Josef-Sugg-Str. 5, 88348 Bad Saulgau, Germany
  • Kapellenstraße 27, 47533 Kleve-Materborn, Germany
  • Kleinenbroicher Str. 68, 41352 Korschenbroich, Germany
  • Kuhtrift 8a, 34414 Warburg, Germany
  • Langenbeckstraße 1, 55101 Mainz, Germany
  • Lindenpromenade 34b, 39164 Wanzleben, Germany
  • Lindenstr. 9, 25524 Itzehoe, Germany
  • Marienstraße 2, 44866 Bochum, Germany
  • Maschstr. 8a, 49565 Bramsche, Germany
  • Mose-Stern-Str. 28, 41236 Mönchengladbach, Germany
  • Ostlandstr. 10, 32339 Espelkamp, Germany
  • Poststr. 10, 34225 Baunatal, Germany
  • Tangstedter Landstr 77, 22415 Hamburg, Germany
  • Wilhelmshöher Allee 109, 34121 Kassel, Germany
  • Würzburger Str. 1, 97941 Tauberbischofsheim, Germany
  • C.so Mazzini 18, 28100 Novar, Italy
  • Current address: Via Luca Giordano n. 13, 50132 Firenze, Italy
  • Piazza Ospedale 10, 20900 Lodi, Italy
  • Via Commenda 9, 20122, Milano, Italy
  • Via Consolare Valeria 1, 98125 Messina, Italy
  • Via G.B.Grossi 74, 20157 Milano, Italy
  • Via Giustiniani,3, 35128 Padova, Italy
  • Via Pastore 1,16132 Genova, Italy
  • Via Siracusa, 45, 90143 Palermo, Italy
  • Viale Pieraccini n. 24 50139 Firenze, Italy
  • Avda. Rambleta, s/n Catarroja Valencia, Spain
  • C/ Tossal del Rei nº 7 Castellón de la Plana Castellón, Spain
  • Catarroja Esquina Ministro Serrano. Paiporta Valencia, Spain
  • Celestino Villamil, s/n Oviedo, Spain
  • Ctra. Anfondeguilla, s/n Vall Duixo Castellón, Spain
  • Isabel de Villena,2 Pabellón Valencia, Spain
  • Molí s/n Puçol Valencia, Spain
  • Médico Fernando Moray de la Horra, 2 acceso Y9 Valencia, Spain
  • Pedro s/n Almazora Castellón, Spain
  • Pizarro, 22 Vigo Pontevedra, Spain
  • Plaza Blasco Ibañez, 4 Sagunto Valencia, Spain
  • Plaza Segovia s/n Valencia, Spain
  • República Argentina nº 8, Valencia, Spain
  • Rosales, 23 La Eliana Valencia, Spain
  • Serreria,73 Valencia, Spain
  • Travesía da Choupana, s/n Santiago de Compostela A Coruña, Spain
  • University Hospitals Bristol, NHS Foundation Trust, Trust Headquarters
    Marlborough Street, Bristol BS1 3NU, United Kingdom
  • South West Medicines for Children Research Network, Child Health Building, Royal Devon and Exeter NHS Foundation Trust
    Barrack Road, Exeter EX2 5DW, United Kingdom
  • St. George's University of London
    Cranmer Terrace, London SW17 0RE, United Kingdom
  • Oxford Vaccines Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road
    Headington, Oxford OX3 7LJ, United Kingdom
  • Centre for Clinical Vaccinology
    Oxford, OX3 7LJ, United Kingdom
10

References and documents

Publications

  • Bartolini E, Borgogni E, Bruttini M, Muzzi A, Giuliani M, Iozzi S, Petracca R, Martinelli M, Bonacci S, Marchi S, Brettoni C, Donati C, Torricelli G, Guidotti S, Domina M, Beninati C, Teti G, Felici F, Rappuoli R, Castellino F, Del Giudice G, Masignani V, Pizza M, Maione D. Immunological fingerprint of 4CMenB recombinant antigens via protein microarray reveals key immunosignatures correlating with bactericidal activity. Nat Commun. 2020 Oct 5;11(1):4994. doi: 10.1038/s41467-020-18791-0. PubMed 33020485 ↗
  • Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, Dull PM, Kohl I, Barone M, Wang H, Toneatto D, Pollard AJ; European MenB Vaccine Study Group. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. Pediatr Infect Dis J. 2016 Apr;35(4):e113-23. doi: 10.1097/INF.0000000000001056. Erratum In: Pediatr Infect Dis J. 2020 Jul;39(7):e162. doi: 10.1097/INF.0000000000002754. PubMed 26756390 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Aug 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2009
First posted
Jul 22, 2009
Start
Jul 2009
Primary completionActual
Aug 2011
CompletionActual
Jan 2012
Results first posted
Nov 10, 2015
Last update
Aug 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00944034
Lead sponsor
Novartis Vaccines
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 22, 2009
Start date
Jul 2009
Primary completion
Aug 2011
Completion
Jan 2012
Results posted
Nov 10, 2015
Last update
Aug 14, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion